taken from the 2022 annual report:
The broad research partnership is material to Imugene as it includes the development of Imugene’s onCARlytics CD19 oncolytic virus licensed from the City of Hope® with Celularity’s allogeneic CAR T-cell therapy (CyCART-19) and has the potential to become a new approach to improve outcomes for patients with solid tumours.
The research collaboration agreement, effective 5 August 2021, has an initial term of 12 months. Following the successful completion
of the pre-clinical research, the parties will negotiate in good faith a collaboration agreement on commercially reasonable terms.
most likely nothing
Ann: IMUGENE ANNOUNCES A$80 MILLION INSTITUTIONAL PLACEMENT, page-293
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.2¢ | 4.9¢ | $531.4K | 10.66M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 3429444 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 149299 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |